Page 1 of Clinical Trials for Drug Alemtuzumab Campath, 270 Total Matches
- 1Not yet recruitingLast Updated: April 19, 2006Condition(s): Pancreas-Kidney Transplantation
- 2CompletedEffectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted KidneysLast Updated: September 13, 2010Condition(s): Graft Rejection; Kidney Disease
- 3Active, not recruitingLast Updated: July 15, 2011Condition(s): Myelodysplastic and Myeloproliferative Disorders; Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Chronic Myelogenous Leukemia; Multiple Myeloma; Plasma Cell Dyscrasia; Lymphoproliferative Disorders; Hematologic Diseases
- 4CompletedLast Updated: August 9, 2011Condition(s): Kidney Transplantation
- 5TerminatedLast Updated: May 9, 2012Condition(s): Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell
- 6RecruitingLast Updated: October 10, 2008Condition(s): Organ Transplantation
- 7CompletedLast Updated: December 21, 2010Condition(s): Immunologic Deficiency Syndrome
- 8CompletedLast Updated: December 2, 2009Condition(s): Hematologic Malignancy
- 9Active, not recruitingLast Updated: August 5, 2011Condition(s): Evidence of Liver Transplantation; Rejection; ALEMTUZUMAB/NATALIZUMAB [VA Drug Interaction]
- 10RecruitingLast Updated: June 27, 2011Condition(s): End-stage Renal Failure; Graft Rejection
- 11RecruitingLast Updated: June 2, 2011Condition(s): Metabolic Disorders; Hematologic, Immune, or Bone Marrow Disorders; Hemoglobinopathies
- 12RecruitingLast Updated: April 11, 2012Condition(s): Hematologic Malignancies
- 13RecruitingLast Updated: May 12, 2012Condition(s): Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma
- 14WithdrawnLast Updated: December 28, 2011Condition(s): Chronic Lymphocytic Leukaemia; Patients Resistant to a Purine Analogous; Patients Relapsed With Purines Therapy
- 15TerminatedLast Updated: August 18, 2009Condition(s): Acute Rejection; Renal Transplantation
- 16Active, not recruitingLast Updated: May 9, 2008Condition(s): Kidney Transplantation; Kidney Diseases; Kidney Failure
- 17RecruitingLast Updated: March 20, 2012Condition(s): Peripheral Blood Stem Cell Transplantation; Anemia, Sickle Cell; Graft-Versus-Host Disease; Sirolimus (Rapamune(Registered Trademark)); Alemtuzumab (Campath(Registered Trademark))
- 18CompletedLast Updated: January 3, 2012Condition(s): Leukemia, Lymphocytic, Chronic, B-Cell
- 19RecruitingLast Updated: April 10, 2012Condition(s): Leukemia; Hodgkin Lymphoma; Non Hodgkin Lymphoma; Myeloproliferative Disorders
- 20Active, not recruitingLast Updated: January 10, 2011Condition(s): Graft Rejection
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=Drug+Alemtuzumab+Campath
